Elacestrant Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 200 mg
Reference Brands: Orserdu (USA/EU)
Category:
Oncology Cancer Care
Elacestrant is available in Tablets
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Elacestrant is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Elacestrant can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Elacestrant is a selective antiestrogen medication that functions as an estrogen receptor antagonist, blocking the activity of estrogen in estrogen receptor (ER)-positive breast cancer cells. By inhibiting estrogen receptor signaling, elacestrant helps slow or stop the growth of cancer cells that depend on estrogen for proliferation. It is particularly designed for postmenopausal women and adult men with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one prior line of endocrine therapy.
Elacestrant is administered orally as a convenient tablet formulation, providing an effective alternative to injectable selective estrogen receptor degraders (SERDs). Its use targets tumors driven by estrogen receptor signaling, helping to control disease progression in patients with resistant breast cancer. Common side effects associated with elacestrant include body pain, nausea and vomiting, fatigue, elevated liver enzymes, increased serum lipids, decreased hemoglobin, raised creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, and hot flashes. With its targeted mechanism of action, elacestrant offers a critical option for patients with advanced or metastatic ER-positive breast cancer who have limited treatment choices.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing